Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
TEST DOSE-GUIDED ADMINISTRATION OF CISPLATIN IN AN ANEPHRIC PATIENT -A CASE-REPORT
Autore:
RIBRAG V; DROZ JP; MORIZET J; LECLERCQ B; GOUYETTE A; CHABOT GG;
Indirizzi:
INST GUSTAVE ROUSSY,INTENS CARE UNIT,PAVILLON RECH 2 F-94805 VILLEJUIF FRANCE INST GUSTAVE ROUSSY,INTENS CARE UNIT,PAVILLON RECH 2 F-94805 VILLEJUIF FRANCE INST GUSTAVE ROUSSY,DEPT MED F-94805 VILLEJUIF FRANCE INST GUSTAVE ROUSSY,CLIN PHARMACOL LAB,INSERM,U140 F-94805 VILLEJUIF FRANCE INST GUSTAVE ROUSSY,CNRS,URA 147 F-94805 VILLEJUIF FRANCE
Titolo Testata:
Annals of oncology
fascicolo: 8, volume: 4, anno: 1993,
pagine: 679 - 682
SICI:
0923-7534(1993)4:8<679:TDAOCI>2.0.ZU;2-2
Fonte:
ISI
Lingua:
ENG
Soggetto:
RENAL-FUNCTION; PLATINUM; PHARMACOKINETICS; HEMODIALYSIS; KINETICS; DOSAGE;
Keywords:
CISPLATIN ADMINISTRATION; ANEPHRIC PATIENT;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
19
Recensione:
Indirizzi per estratti:
Citazione:
V. Ribrag et al., "TEST DOSE-GUIDED ADMINISTRATION OF CISPLATIN IN AN ANEPHRIC PATIENT -A CASE-REPORT", Annals of oncology, 4(8), 1993, pp. 679-682

Abstract

Background: Although cisplatin pharmacokinetics is well documented inpatients with various degrees of renal dysfunction, no information isavailable concerning cisplatin administration to anephric patients. Since anephric patients may sometimes need cisplatin therapy, it is therefore of importance to define therapeutic guidelines for cisplatin administration in this patient population. Patient and methods: Cisplatin was administered to an anephric patient (bilateral nephrectomy) requiring cisplatin therapy for a metastatic carcinoma of the urothelium. A test dose of 12 mg (7.5 mg/m2) of cisplatin was first administered as a 1 hour infusion in order to determine the patient's pharmacokinetic parameters. Filterable and total platinum levels were determined by flameless atomic absorption spectrophotometry. Haemodialysis was started 30 min before the beginning of the cisplatin infusion and was maintained for 4 h thereafter. Results: Under haemodialysis, filterable andtotal platinum pharmacokinetics after the test dose were comparable with a patient with normal renal function, i.e. with peak plasma concentrations of 126 ng/ml and 166 ng/ml for the filterable and the total platinum, respectively. The area under the curves (AUC) were 154 ng.h/ml for the filterable and 11486 ng.h/ml for the total platinum. The terminal half-lives of filterable and total platinum were 0.42 h and 101 h, respectively. Based on the test dose platinum pharmacokinetics, a therapeutic dose of 100 mg (63 mg/m2) of cisplatin was administered. Following the therapeutic dose, peak plasma concentrations reached 1,120ng/ml for the filterable and 1,280 ng/ml for the total platinum. The AUCs were 1,609 and 65,556 ng.h/ml for the filterable and the total platinum, respectively, as expected from the predicted AUCs obtained from the test dose pharmacokinetics. The terminal half-lives of filterable and total platinum were similar to the ones observed after the test dose, i.e. 0.36 h and 86 h, respectively. Although the patient died ofrapidly progressive hepatic failure, the feasibility of the test dose-guided cisplatin administration in an anephric patient is demonstrated. Conclusion: This approach may be helpful in monitoring cisplatin therapy in similar cases requiring cisplatin administration.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 24/11/20 alle ore 08:24:15